ATE169621T1 - Hydroxamsaeurederivate als metalloproteinase inhibitoren - Google Patents

Hydroxamsaeurederivate als metalloproteinase inhibitoren

Info

Publication number
ATE169621T1
ATE169621T1 AT94909201T AT94909201T ATE169621T1 AT E169621 T1 ATE169621 T1 AT E169621T1 AT 94909201 T AT94909201 T AT 94909201T AT 94909201 T AT94909201 T AT 94909201T AT E169621 T1 ATE169621 T1 AT E169621T1
Authority
AT
Austria
Prior art keywords
alkyl
group
phenyl
pct
hydrogen atom
Prior art date
Application number
AT94909201T
Other languages
English (en)
Inventor
Michael John Crimmin
Paul Raymond Beckett
Mark Hampton Davis
Original Assignee
British Biotech Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939305348A external-priority patent/GB9305348D0/en
Priority claimed from GB939320360A external-priority patent/GB9320360D0/en
Application filed by British Biotech Pharm filed Critical British Biotech Pharm
Application granted granted Critical
Publication of ATE169621T1 publication Critical patent/ATE169621T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT94909201T 1993-03-16 1994-03-14 Hydroxamsaeurederivate als metalloproteinase inhibitoren ATE169621T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939305348A GB9305348D0 (en) 1993-03-16 1993-03-16 Hydroxamic acid derivatives as metalloproteinase inhibitors
GB939320360A GB9320360D0 (en) 1993-10-02 1993-10-02 Hydroxamic acid derivatives as metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
ATE169621T1 true ATE169621T1 (de) 1998-08-15

Family

ID=26302598

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94909201T ATE169621T1 (de) 1993-03-16 1994-03-14 Hydroxamsaeurederivate als metalloproteinase inhibitoren

Country Status (12)

Country Link
US (1) US5652262A (de)
EP (1) EP0689538B1 (de)
JP (1) JPH08508027A (de)
AT (1) ATE169621T1 (de)
AU (1) AU671724B2 (de)
CA (1) CA2158352A1 (de)
DE (1) DE69412469T2 (de)
FI (1) FI954351A7 (de)
GB (1) GB2290543B (de)
NO (1) NO953652D0 (de)
NZ (1) NZ262447A (de)
WO (1) WO1994021625A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9404046D0 (en) * 1994-03-03 1994-04-20 Smithkline Beecham Corp Novel compounds
GB9414157D0 (en) * 1994-07-13 1994-08-31 Smithkline Beecham Plc Medical use
GB9601042D0 (en) * 1996-01-17 1996-03-20 Smithkline Beecham Plc Medical use
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US6017887A (en) * 1995-01-06 2000-01-25 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
GB9502858D0 (en) * 1995-02-14 1995-04-05 British Biotech Pharm Novel use of matrix metalloproteinase inhibitors
WO1996030381A1 (en) * 1995-03-28 1996-10-03 Novo Nordisk A/S Immunosuppressive agents
GB9507799D0 (en) * 1995-04-18 1995-05-31 British Biotech Pharm Metalloproteinase inhibitors
US5917090A (en) * 1995-06-30 1999-06-29 British Biotech Pharmaceuticals Ltd. Matrix metalloproteinase inhibitors
AU2986295A (en) * 1995-07-19 1997-02-18 British Biotech Pharmaceuticals Limited N-(amino acid) substituted succinic acid amide derivatives as metalloproteinase inhibitors
US5665777A (en) * 1995-11-14 1997-09-09 Abbott Laboratories Biphenyl hydroxamate inhibitors of matrix metalloproteinases
ATE205184T1 (de) 1995-11-23 2001-09-15 British Biotech Pharm Metalloproteinase inhibitoren
GB9609702D0 (en) 1996-05-09 1996-07-10 Royal Free Hosp School Med Anticoagulant peptides
DE69714056T2 (de) 1996-09-10 2003-02-27 British Biotech Pharmaceuticals Ltd., Cowley Cytostatische hydroxamsäurederivate
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
GB9619631D0 (en) * 1996-09-20 1996-11-06 British Biotech Pharm Combination therapy
US5840974A (en) * 1996-12-04 1998-11-24 Britisch Biotech Pharmaceuticals, Ltd. Metalloproteinase inhibitors
JP3973748B2 (ja) * 1998-01-14 2007-09-12 花王株式会社 発毛抑制剤
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
HUP0105412A2 (hu) * 1999-01-13 2002-05-29 Jomaa Pharmaka Gmbh. 3-Izoxazolidinon- és karboxi-alkil-hidroxámsav-származékok alkalmazása fertőzések kezelésére szolgáló gyógyszerkészítmények előállítására
GB9901863D0 (en) * 1999-01-29 1999-03-17 British Biotech Pharm Antibacterial agents
US6297337B1 (en) 1999-05-19 2001-10-02 Pmd Holdings Corp. Bioadhesive polymer compositions
US6797820B2 (en) * 1999-12-17 2004-09-28 Vicuron Pharmaceuticals Inc. Succinate compounds, compositions and methods of use and preparation
EP1306367B1 (de) 2000-07-19 2007-07-18 Mitsubishi Pharma Corporation Sulphonsäurederivate von hydroxamsäuren und deren verwendung in medizinischen produkten
EP1596846A2 (de) * 2003-02-18 2005-11-23 Pfizer Inc. Zusammensetzungen enthaltend hepatitis c virus hemmer und deren verwendung zur behandlung
WO2004101537A1 (en) * 2003-05-17 2004-11-25 British Biotech Pharmaceuticals Ltd Metalloproteinase inhibitors
US7419801B2 (en) 2003-08-08 2008-09-02 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
CA2559062A1 (en) 2004-03-09 2005-09-22 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
WO2007141029A1 (en) * 2006-06-08 2007-12-13 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Specific protease inhibitors and their use in cancer therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
GB8919251D0 (en) * 1989-08-24 1989-10-04 British Bio Technology Compounds
JPH05503720A (ja) * 1990-12-03 1993-06-17 セルテック リミテッド ペプチジル誘導体
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds
JPH05125029A (ja) * 1991-11-06 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアミド化合物又はその塩
GB9211706D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives

Also Published As

Publication number Publication date
FI954351A0 (fi) 1995-09-15
NO953652L (no) 1995-09-15
DE69412469D1 (de) 1998-09-17
EP0689538B1 (de) 1998-08-12
DE69412469T2 (de) 1999-02-04
NZ262447A (en) 1996-07-26
GB2290543A (en) 1996-01-03
EP0689538A1 (de) 1996-01-03
WO1994021625A1 (en) 1994-09-29
GB9517704D0 (en) 1995-11-01
GB2290543B (en) 1996-05-22
FI954351A7 (fi) 1995-09-15
AU671724B2 (en) 1996-09-05
US5652262A (en) 1997-07-29
NO953652D0 (no) 1995-09-15
JPH08508027A (ja) 1996-08-27
AU6213194A (en) 1994-10-11
CA2158352A1 (en) 1994-09-29

Similar Documents

Publication Publication Date Title
ATE169621T1 (de) Hydroxamsaeurederivate als metalloproteinase inhibitoren
WO1991002716A3 (en) Hydroxamic acid based collagenase inhibitors
NO911962D0 (no) Hydroksaminsyrebaserte kollagenaseinhibitorer.
ES2063334T3 (es) Inhibidores de la colagenasa basados en el acido hidroxamico.
ATE279391T1 (de) Anti-imflammtorische indolderivate
LU91140I2 (fr) Duloxètine et ses sels d'addition acides pharmaceutiquement acceptables et particulièrement chlorhydrate de duloxétine (ARICLAIM).
DK1252133T3 (da) Farmaceutiske forbindelser
BR9909398A (pt) Composto, medicamento, processo para impedir ou tratar a artrite, processo para inibir a metástase, a invasão ou o desenvolvimento do câncer, e, uso do composto
DE69424147D1 (de) Vorrichtung für die vaginale Verabreichung von Tamoxifen und dessen Analogen
DK1295871T3 (da) Vitamin D-derivater med et 22-oxa- eller 22-thiaatom, en C17-sidekæde substitueret med en syre-, ester- eller amid-gruppe og en 16(17)-dobbeltbinding
ATE244229T1 (de) Thiadiazolyl(thio)harnstoffe und ihre verwendung als matrix-metallprotease inhibitoren
IL150965A0 (en) Therapeutic or preventive agent for digestive system diseases containing a diaminotrifluoromethylpyridine derivative
NO305165B1 (no) 1-Arylcykloalkylsulfider, -sulfoksyder og -sulfoner, farmas°ytiske preparater og anvendelse derav
ATE99934T1 (de) Heteroaryl-3-oxo-propannitril-derivate, nuetzlich zur behandlung von rheumatoider arthritis und anderen autoimmunkrankheiten.
IL122247A0 (en) Use of sulfamic acid derivatives acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein levels
DE69414396D1 (de) Acylphenylglycin-derivat und dieses als aktivbestandteil enthaltendes vorbeugungs -und heilmittel gegen durch erhöhte collagenaseaktivität verursachte krankheiten
DE60113808D1 (de) Therapeutikum oder Prophylaktikum für Lebererkrankungen, enthaltend ein Diaminotrifluorethylpyridin-Derivat
DE68913159D1 (de) Thiophencarboxamid-Derivate und ihre Verwendung als Heilmittel.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties